The global growth hormone drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing prevalence of obesity and diabetes, which are major risk factors for GH deficiency. Growth hormone deficiency can lead to a number of complications such as osteoporosis, cardiovascular disease, and type 2 diabetes mellitus.
Norditropin is the most commonly prescribed GH drug in North America and Europe due to its high efficacy and low cost. Genotropin has been approved by FDA for use in children with GHD who are not obese or diabetic; it has also been approved by EMA for use in adults with GHD who are not obese or diabetic. Nutropin was developed by Pfizer Inc, but it is no longer marketed because Pfizer Inc, discontinued its production of human growth hormone drugs on December 31st, 2009 after acquiring Wyeth Pharmaceuticals (now part of Pfizer).
Some Of The Growth Factors Of This Market:
- Growth hormone deficiency is a condition that affects many people, and the number of people with this condition is expected to increase as the population ages.
- The use of growth hormone drugs has been shown to improve quality of life for those with growth hormone deficiency, and it can also help prevent or delay some age-related diseases such as diabetes and heart disease.
- Growth hormone drugs are expensive, which limits their use in some countries where they are not covered by insurance or other healthcare programs.
- There are side effects associated with growth hormone drug use, including joint pain and carpal tunnel syndrome; these side effects may be more common in older adults who take these drugs long-term than in younger adults who take them for short periods of time to treat a specific medical condition such as short stature or Turner syndrome.
- The cost of treatment may be prohibitive for some patients.
Industry Growth Insights published a new data on “Growth Hormone Drug Market”. The research report is titled “Growth Hormone Drug Market research by Types (Norditropin, Genotropin, Humatrope, Saizen, Nutropin), By Applications (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Players/Companies Merck, Roche, Novartis, Novo Nordisk, Eli Lilly, Pfizer, LG, Aeterna Zentaris, Biogenomics, Critical Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Growth Hormone Drug Market Research Report
By Type
Norditropin, Genotropin, Humatrope, Saizen, Nutropin
By Application
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
By Companies
Merck, Roche, Novartis, Novo Nordisk, Eli Lilly, Pfizer, LG, Aeterna Zentaris, Biogenomics, Critical Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Growth Hormone Drug Market Report Segments:
The global Growth Hormone Drug market is segmented on the basis of:
Types
Norditropin, Genotropin, Humatrope, Saizen, Nutropin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Roche
- Novartis
- Novo Nordisk
- Eli Lilly
- Pfizer
- LG
- Aeterna Zentaris
- Biogenomics
- Critical Pharmaceuticals
Highlights of The Growth Hormone Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Norditropin
- Genotropin
- Humatrope
- Saizen
- Nutropin
- By Application:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Growth Hormone Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Growth hormone (GH) is a peptide hormone that stimulates the body's natural growth and development. GH is produced by the pituitary gland, which is located at the base of the brain. GH plays an important role in childhood growth and development, as well as in maintaining muscle mass during adulthood.
Some of the major players in the growth hormone drug market are Merck, Roche, Novartis, Novo Nordisk, Eli Lilly, Pfizer, LG, Aeterna Zentaris, Biogenomics, Critical Pharmaceuticals.
The growth hormone drug market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Growth Hormone Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Growth Hormone Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Growth Hormone Drug Market - Supply Chain
4.5. Global Growth Hormone Drug Market Forecast
4.5.1. Growth Hormone Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Growth Hormone Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Growth Hormone Drug Market Absolute $ Opportunity
5. Global Growth Hormone Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Growth Hormone Drug Market Size and Volume Forecast by Type
5.3.1. Norditropin
5.3.2. Genotropin
5.3.3. Humatrope
5.3.4. Saizen
5.3.5. Nutropin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Growth Hormone Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Growth Hormone Drug Market Size and Volume Forecast by Application
6.3.1. Retail Pharmacies
6.3.2. Hospital Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Growth Hormone Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Growth Hormone Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Growth Hormone Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Growth Hormone Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Growth Hormone Drug Demand Share Forecast, 2019-2026
9. North America Growth Hormone Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Growth Hormone Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Growth Hormone Drug Market Size and Volume Forecast by Application
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Growth Hormone Drug Market Size and Volume Forecast by Type
9.7.1. Norditropin
9.7.2. Genotropin
9.7.3. Humatrope
9.7.4. Saizen
9.7.5. Nutropin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Growth Hormone Drug Demand Share Forecast, 2019-2026
10. Latin America Growth Hormone Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Growth Hormone Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Growth Hormone Drug Market Size and Volume Forecast by Application
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Growth Hormone Drug Market Size and Volume Forecast by Type
10.7.1. Norditropin
10.7.2. Genotropin
10.7.3. Humatrope
10.7.4. Saizen
10.7.5. Nutropin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Growth Hormone Drug Demand Share Forecast, 2019-2026
11. Europe Growth Hormone Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Growth Hormone Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Growth Hormone Drug Market Size and Volume Forecast by Application
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Growth Hormone Drug Market Size and Volume Forecast by Type
11.7.1. Norditropin
11.7.2. Genotropin
11.7.3. Humatrope
11.7.4. Saizen
11.7.5. Nutropin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Growth Hormone Drug Demand Share, 2019-2026
12. Asia Pacific Growth Hormone Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Growth Hormone Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Growth Hormone Drug Market Size and Volume Forecast by Application
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Growth Hormone Drug Market Size and Volume Forecast by Type
12.7.1. Norditropin
12.7.2. Genotropin
12.7.3. Humatrope
12.7.4. Saizen
12.7.5. Nutropin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Growth Hormone Drug Demand Share, 2019-2026
13. Middle East & Africa Growth Hormone Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Growth Hormone Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Growth Hormone Drug Market Size and Volume Forecast by Application
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Growth Hormone Drug Market Size and Volume Forecast by Type
13.7.1. Norditropin
13.7.2. Genotropin
13.7.3. Humatrope
13.7.4. Saizen
13.7.5. Nutropin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Growth Hormone Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Growth Hormone Drug Market: Market Share Analysis
14.2. Growth Hormone Drug Distributors and Customers
14.3. Growth Hormone Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novo Nordisk
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. LG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Aeterna Zentaris
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biogenomics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Critical Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
